"Shares of Pfizer (NYSE: PFE) lost 9.90% over the past month after gaining 10.02% the month prior. The stock's year-to-date loss now stands at 7.33%. Over the past year, PFE has fallen by 11.17%. The recent rally in the Big Pharma stock can be attributed to the Trump administration announcing a plan for TrumpRx, which seeks to lower prescription costs for Americans, with Pfizer working in partnership with the federal government. When the Big Pharma lynchpin is slated to report Q3 earnings on Tuesday, Nov. 4."
"This summer, the FDA announced it will only be recommending COVID-19 vaccines for seniors aged 65 and older and those with certain medical conditions, excluding healthy adults and children above a certain age from its recommendation. That may act as a severe headwind for Pfizer, whose coronavirus franchise - Paxlovid and Comirnaty - contributed $11.1 billion in combined revenue in 2024. Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis."
Shares of Pfizer recently reversed a prior monthly gain and now show a year-to-date decline of 7.33% and an 11.17% drop over one year. A government partnership under the TrumpRx plan helped a short rally, while an FDA decision to limit COVID-19 vaccine recommendations to seniors and certain medically vulnerable groups shrinks the vaccine market. Pfizer's COVID franchise, Paxlovid and Comirnaty, produced $11.1 billion in 2024, and non-COVID drugs like Vyndaquel, Padcev and Eliquis also supported year-end strength. The company yields 6.31% in dividends and faces upcoming Q3 results on Nov. 4.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]